Effectiveness of defibrotide for prophylaxis of deep venous thrombosis in gynecological surgery: a double-blind, placebo-controlled clinical trial. 1986

N Ciavarella, and C Ettorre, and M Schiavoni, and S Schonauer, and E Cicinelli, and G Cagnazzo

Defibrotide, a new antithrombotic compound without anticoagulant activity, has been tested for prevention of deep venous thrombosis (DVT) in patients undergoing gynecological surgery (mainly hysterectomy). Eighty-nine women (mean age 48.5) were randomly allocated to defibrotide (44 patients) or placebo (45 patients). 800 mg defibrotide was given daily (200 mg intravenously 4 times a day), starting on the day before operation and then for the next 7 days. DVT were detected by the conventional 125I-fibrinogen test. The two groups were homogeneous for known risk factors (age, varicosities, obesity, neoplasia and previous thromboembolic episodes). The results showed a statistically significant reduction of DVT incidence in patients on defibrotide, as compared with those on placebo: 4/44 = 9% vs. 13/45 = 28.8% (p less than 0.05). There were no side effects, including hemorrhagic complications. The numbers of units transfused were comparable for the 2 groups. In conclusion, the trial shows that defibrotide is an effective and safe drug for the prevention of DVT in gynecological surgery.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011089 Polydeoxyribonucleotides A group of 13 or more deoxyribonucleotides in which the phosphate residues of each deoxyribonucleotide act as bridges in forming diester linkages between the deoxyribose moieties. Polydeoxyribonucleotide
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D005831 Genital Diseases, Female Pathological processes involving the female reproductive tract (GENITALIA, FEMALE). Gynecologic Diseases,Female Genital Diseases,Diseases, Female Genital,Diseases, Gynecologic,Female Genital Disease,Genital Disease, Female,Gynecologic Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

N Ciavarella, and C Ettorre, and M Schiavoni, and S Schonauer, and E Cicinelli, and G Cagnazzo
January 1986, Haemostasis,
N Ciavarella, and C Ettorre, and M Schiavoni, and S Schonauer, and E Cicinelli, and G Cagnazzo
January 1990, International surgery,
N Ciavarella, and C Ettorre, and M Schiavoni, and S Schonauer, and E Cicinelli, and G Cagnazzo
January 1992, Haematologica,
N Ciavarella, and C Ettorre, and M Schiavoni, and S Schonauer, and E Cicinelli, and G Cagnazzo
July 1993, British heart journal,
N Ciavarella, and C Ettorre, and M Schiavoni, and S Schonauer, and E Cicinelli, and G Cagnazzo
December 1992, The Southeast Asian journal of tropical medicine and public health,
N Ciavarella, and C Ettorre, and M Schiavoni, and S Schonauer, and E Cicinelli, and G Cagnazzo
December 2016, The Lancet. Haematology,
N Ciavarella, and C Ettorre, and M Schiavoni, and S Schonauer, and E Cicinelli, and G Cagnazzo
February 2010, International journal of oral and maxillofacial surgery,
N Ciavarella, and C Ettorre, and M Schiavoni, and S Schonauer, and E Cicinelli, and G Cagnazzo
February 2000, Obstetrics and gynecology,
N Ciavarella, and C Ettorre, and M Schiavoni, and S Schonauer, and E Cicinelli, and G Cagnazzo
February 2019, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,
N Ciavarella, and C Ettorre, and M Schiavoni, and S Schonauer, and E Cicinelli, and G Cagnazzo
March 2005, Journal of the American College of Surgeons,
Copied contents to your clipboard!